Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade D 84.1 0.63% 0.53
BMRN closed up 0.63 percent on Friday, March 16, 2018, on 1.26 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical BMRN trend table...

Date Alert Name Type % Chg
Mar 16 Wide Bands Range Expansion 0.00%
Mar 15 Stochastic Sell Signal Bearish 0.63%
Mar 15 Wide Bands Range Expansion 0.63%
Mar 15 Overbought Stochastic Strength 0.63%
Mar 14 50 DMA Resistance Bearish -2.15%
Mar 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.15%
Mar 14 Outside Day Range Expansion -2.15%
Mar 14 Wide Bands Range Expansion -2.15%
Mar 14 Overbought Stochastic Strength -2.15%
Mar 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.39%

Older signals for BMRN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Is BMRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 100.51
52 Week Low 77.045
Average Volume 1,369,980
200-Day Moving Average 87.7999
50-Day Moving Average 86.3705
20-Day Moving Average 83.144
10-Day Moving Average 83.704
Average True Range 2.4356
ADX 21.84
+DI 18.65
-DI 26.19
Chandelier Exit (Long, 3 ATRs ) 79.4332
Chandelier Exit (Short, 3 ATRs ) 84.3518
Upper Bollinger Band 87.2166
Lower Bollinger Band 79.0714
Percent B (%b) 0.62
BandWidth 9.796498
MACD Line -0.3517
MACD Signal Line -0.8792
MACD Histogram 0.5276
Fundamentals Value
Market Cap 14.74 Billion
Num Shares 175 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -78.60
Price-to-Sales 12.04
Price-to-Book 5.17
PEG Ratio -4.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 86.32
Resistance 3 (R3) 86.10 85.14 85.95
Resistance 2 (R2) 85.14 84.57 85.25 85.83
Resistance 1 (R1) 84.62 84.23 84.88 84.84 85.70
Pivot Point 83.66 83.66 83.79 83.77 83.66
Support 1 (S1) 83.14 83.09 83.40 83.36 82.50
Support 2 (S2) 82.18 82.75 82.29 82.37
Support 3 (S3) 81.66 82.18 82.25
Support 4 (S4) 81.88